Guadecitabine Plus Ipilimumab in Unresectable Melanoma: Five-Year Follow-Up and Integrated Multi-Omic Analysis in the Phase 1b NIBIT-M4 Trial [PDF]
Association with hypomethylating agents is a promising strategy to improve the efficacy of immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation trial in patients with advanced melanoma of the hypomethylating agent ...
Andrea Anichini +2 more
exaly +8 more sources
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation [PDF]
Background The yearly Think Tank Meeting of the Italian Network for Tumor Biotherapy (NIBIT) Foundation, brings together in Siena, Tuscany (Italy), experts in immuno-oncology to review the learnings from current immunotherapy treatments, and to propose ...
Michele Maio +7 more
doaj +19 more sources
The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward
As for a consolidated tradition, the 5th annual meeting of the Italian Network for Cancer Biotherapy took place in the Certosa of Pontignano, a Tuscan monastery, on September 20–22, 2007.
Ridolfi Ruggero +11 more
doaj +6 more sources
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy [PDF]
Background Improvement of efficacy of immune checkpoint blockade (ICB) remains a major clinical goal. Association of ICB with immunomodulatory epigenetic drugs is an option.
Andrea Anichini +23 more
doaj +2 more sources
Highlighting recent achievements to advance more effective cancer immunotherapy [PDF]
From 17 to 19th October 2024, the XXI Italian Network for Bio-Immunotherapy of Tumors Meeting (NIBIT) took place in Palermo, in the marvelous historical location of Teatro Politeama, under the auspices of the Italian Association of Medical Oncology (AIOM)
Beatrice Belmonte +14 more
doaj +2 more sources
Background The combination of Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) blockade has dramatically improved the overall survival rate for malignant melanoma.
Adriana Amaro +23 more
doaj +1 more source
Antibodies to immune checkpoints have entered the clinical arena and have been shown to provide a clinical benefit for metastatic melanoma and, possibly, for other tumors as well. In this review paper we summarize this therapeutic activity and underline
Giorgio Parmiani +2 more
doaj +1 more source
Background: Ipilimumab plus nivolumab (COMBO) is the standard treatment in patients with asymptomatic melanoma brain metastases (MBM) (1)(2)(3). We report a retrospective study aiming to assess the outcome of patients with MBM treated with COMBO with or
Italian Melanoma Intergroup
doaj +1 more source
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an ...
Luana Calabrò +21 more
doaj +1 more source
Cancer Bio-Immunotherapy XVIII Annual NIBIT-(Italian Network for Tumor Biotherapy) Meeting, October 15–16, 2020 [PDF]
Arianna Brevi +2 more
exaly +7 more sources

